JO3611B1 - سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم - Google Patents
سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيمInfo
- Publication number
- JO3611B1 JO3611B1 JOP/2012/0223A JOP20120223A JO3611B1 JO 3611 B1 JO3611 B1 JO 3611B1 JO P20120223 A JOP20120223 A JO P20120223A JO 3611 B1 JO3611 B1 JO 3611B1
- Authority
- JO
- Jordan
- Prior art keywords
- naphthyridinone
- cyclopenta
- pyrrole
- dihydro
- antibacterial
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177119 | 2011-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3611B1 true JO3611B1 (ar) | 2020-08-27 |
Family
ID=46650549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2012/0223A JO3611B1 (ar) | 2011-08-10 | 2012-08-07 | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
Country Status (24)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012293619B2 (en) | 2011-08-10 | 2017-05-04 | Janssen Sciences Ireland Uc | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| KR102323873B1 (ko) * | 2012-08-10 | 2021-11-09 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 신규한 항균성 화합물 |
| EP3461827B1 (en) | 2013-09-26 | 2022-02-23 | Cadent Therapeutics, Inc. | Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| ES2788856T3 (es) | 2017-03-20 | 2020-10-23 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| WO2019177975A1 (en) | 2018-03-12 | 2019-09-19 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| KR102872166B1 (ko) | 2018-11-12 | 2025-10-15 | 데비오팜 인터네셔날 에스 에이 | 항생제 화합물, 이의 제조 방법, 이를 포함하는 약학적 조성물 및 그 용도 |
| MA57202B1 (fr) | 2019-09-19 | 2025-09-30 | Novo Nordisk Health Care Ag | Compositions d'activation de la pyruvate kinase r (pkr) |
| WO2022194906A1 (en) * | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| HK1049656A1 (zh) | 1999-10-08 | 2003-05-23 | Smithkline Beecham Corporation | Fab i抑制剂 |
| EP1225895B1 (en) | 1999-10-08 | 2005-05-04 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| AU7866300A (en) | 1999-10-08 | 2001-04-23 | Smithkline Beecham Corporation | Fab i inhibitors |
| DE60230934D1 (de) | 2001-04-06 | 2009-03-05 | Affinium Pharm Inc | Fab-i-inhibitoren |
| DK1828167T3 (da) * | 2004-06-04 | 2014-10-20 | Debiopharm Int Sa | Acrylamidderivater som antibiotiske midler |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| JP5468899B2 (ja) * | 2006-07-20 | 2014-04-09 | アフィニウム ファーマシューティカルズ， インク． | Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 |
| EP2125802A4 (en) | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| CN102656158B (zh) * | 2009-11-18 | 2015-02-11 | Fab药物股份公司 | 新的杂环丙烯酰胺类化合物及其作为药物的用途 |
| WO2013019710A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| US8766017B2 (en) | 2011-07-29 | 2014-07-01 | Eastman Chemical Company | Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| AU2012293619B2 (en) | 2011-08-10 | 2017-05-04 | Janssen Sciences Ireland Uc | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| US9394295B2 (en) | 2011-08-10 | 2016-07-19 | Janssen Sciences Ireland Uc | Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones |
-
2012
- 2012-08-07 JO JOP/2012/0223A patent/JO3611B1/ar active
- 2012-08-10 EA EA201490438A patent/EA201490438A1/ru unknown
- 2012-08-10 AR ARP120102929A patent/AR087508A1/es active IP Right Grant
- 2012-08-10 TW TW101128885A patent/TWI568731B/zh not_active IP Right Cessation
- 2012-08-10 CA CA2842518A patent/CA2842518C/en active Active
- 2012-08-10 WO PCT/EP2012/065733 patent/WO2013021054A1/en not_active Ceased
- 2012-08-10 KR KR1020147005329A patent/KR101996862B1/ko active Active
- 2012-08-10 EP EP12746093.9A patent/EP2742045B1/en active Active
- 2012-08-10 HU HUE12746093A patent/HUE042978T2/hu unknown
- 2012-08-10 PE PE2014000186A patent/PE20141410A1/es active IP Right Grant
- 2012-08-10 PH PH1/2014/500317A patent/PH12014500317A1/en unknown
- 2012-08-10 MX MX2014001600A patent/MX348128B/es active IP Right Grant
- 2012-08-10 UY UY0001034253A patent/UY34253A/es active IP Right Grant
- 2012-08-10 AU AU2012293621A patent/AU2012293621B2/en active Active
- 2012-08-10 BR BR112014003063-4A patent/BR112014003063B1/pt active IP Right Grant
- 2012-08-10 CN CN201280038643.4A patent/CN103874698B/zh active Active
- 2012-08-10 CN CN201511000870.XA patent/CN105461684B/zh active Active
- 2012-08-10 TR TR2019/05537T patent/TR201905537T4/tr unknown
- 2012-08-10 DK DK12746093.9T patent/DK2742045T3/en active
- 2012-08-10 US US14/237,862 patent/US8906923B2/en active Active
- 2012-08-10 JP JP2014524410A patent/JP5921687B2/ja active Active
- 2012-08-10 ES ES12746093T patent/ES2721658T3/es active Active
- 2012-10-08 UA UAA201400628A patent/UA111210C2/uk unknown
-
2014
- 2014-01-20 IL IL230549A patent/IL230549A/en active IP Right Grant
- 2014-02-05 CL CL2014000289A patent/CL2014000289A1/es unknown
- 2014-11-24 US US14/552,108 patent/US9290493B2/en active Active
-
2016
- 2016-03-16 US US15/071,612 patent/US9617262B2/en active Active
- 2016-04-12 JP JP2016079689A patent/JP2016190843A/ja not_active Withdrawn
-
2017
- 2017-03-09 US US15/454,703 patent/US9884864B2/en active Active
- 2017-12-18 US US15/845,854 patent/US10155759B2/en active Active
-
2018
- 2018-11-16 US US16/194,052 patent/US10501463B2/en active Active
-
2019
- 2019-02-26 US US16/286,383 patent/US10526331B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3611B1 (ar) | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم | |
| NZ708928A (en) | Mannose derivatives for treating bacterial infections | |
| WO2014007951A3 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MY198204A (en) | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof | |
| EA201490435A1 (ru) | Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные пиперидинилом | |
| MX2011005934A (es) | Compuestos organicos. | |
| WO2011117145A3 (en) | Pyrrolopyrazine kinase inhibitors | |
| CU20110083A7 (es) | Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas | |
| WO2010063996A3 (en) | Antibacterial compounds | |
| MX360856B (es) | 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas. | |
| EA201101180A1 (ru) | Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы | |
| MX367309B (es) | Nuevos compuestos antibacterianos. | |
| MX2011008043A (es) | Derivados de actagardina. | |
| MX2015001835A (es) | Nuevos compuestos antibacterianos. | |
| WO2013166282A3 (en) | Methods and compositions for treating bacterial infection | |
| PH12013500219A1 (en) | Compounds with antibacterial activity against clostridium | |
| MX357352B (es) | Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico. | |
| MX2013002398A (es) | Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes. | |
| WO2012018662A3 (en) | Fused-imidazoyl compounds useful as antimicrobial agents | |
| TN2011000248A1 (en) | Organic compounds | |
| UA113722C2 (uk) | Фармацевтична композиція |